Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Correction to: Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
Diabetologia ( IF 8.2 ) Pub Date : 2024-02-13 , DOI: 10.1007/s00125-024-06095-7 Matthias Blüher , Julio Rosenstock , Josef Hoefler , Raymond Manuel , Anita M. Hennige
更新日期:2024-02-13
Diabetologia ( IF 8.2 ) Pub Date : 2024-02-13 , DOI: 10.1007/s00125-024-06095-7 Matthias Blüher , Julio Rosenstock , Josef Hoefler , Raymond Manuel , Anita M. Hennige